7 documents found, page 1 of 1
A case of success: complete response to Radium-223 in metastatic castration-res...
Soares De Pinho, Inês; Esperança Martins, Miguel; Machado, Bárbara; Dâmaso, Sara; Brás, Raquel; Cantinho, Guilhermina; Fernandes, Isabel; Costa, LuisRadium-223 dichloride (Ra223) is the first targeted alpha agent approved for treating metastatic castration-resistant prostate cancer (mCRPC) with bone-exclusive disease. A benefit in overall survival and time to the first symptomatic skeletal-related event was shown in the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. However, this trial did not describe a bone scan response to Ra223, an...
Immune-related serious adverse events with immune checkpoint inhibitors: system...
Oliveira, Clara; Mainoli, Beatrice; Duarte, Gonçalo Silva; Machado, Tiago; Tinoco, Rita G.; Esperança Martins, Miguel; Ferreira, Joaquim J; Costa, JoãoPurpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, though uncertainty exists regarding their immune-related safety. The objective of this study was to assess the comparative safety profile (odds ratio) of ICIs and estimate the absolute rate of immune-related serious adverse events (irSAEs) in cancer patients undergoing treatment with ICIs. Methods: We searched for randomized tria...
Immunotherapy around the clock: impact of infusion timing on stage IV melanoma ...
Gonçalves, Lisa; Gonçalves, Duarte; Esteban-Casanelles, Teresa; Barroso, Tiago; Soares De Pinho, Inês; Lopes Brás, Raquel; Esperança Martins, MiguelAlthough the impact of circadian timing on immunotherapy has yet to be integrated into clinical practice, chronoimmunotherapy is an emerging and promising field as circadian oscillations are observed in immune cell numbers as well as the expression of immunotherapy targets, e.g., programmed cell death protein-1 and its ligand programmed death ligand 1. Concurrent retrospective studies suggest that morning infus...
Genomic profiling of sarcomas: a promising weapon in the therapeutic arsenal
Brás, Raquel; Lopez-Presa, Dolores; Esperança Martins, Miguel; Alvim, Cecilia; Gallego Páez, Lina Marcela; Costa, Luis; Fernandes, IsabelSarcomas are rare malignant mesenchymal neoplasms, and the knowledge of tumor biology and genomics is scarce. Chemotherapy is the standard of care in advanced disease, with poor outcomes. Identifying actionable genomic alterations may offer effective salvage therapeutic options when previous lines have failed. Here, we report a retrospective cohort study of sarcoma patients followed at our center and submitted ...
Osteosarcoma pathogenesis leads the way to new target treatments
Fernandes, Isabel; Alvim, Cecilia; Brás, Raquel; Esperança Martins, Miguel; Costa, LuisOsteosarcoma (OS) is a rare condition with very poor prognosis in a metastatic setting. Basic research has enabled a better understanding of OS pathogenesis and the discovery of new potential therapeutic targets. Phase I and II clinical trials are already ongoing, with some promising results for these patients. This article reviews OS pathogenesis and new potential therapeutic targets.
Vasculitis and breast cancer: mind the hint
Esperança Martins, Miguel; Evangelista, Vasco; Fernandes, Salomão; Almeida, RaquelDiffuse alveolar haemorrhage related to an anti-neutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis is an extremely rare form of presentation of breast cancer. Here we report the case of a 77-year-old woman with a histological diagnosis of a papillary ductal carcinoma of the breast presenting with a diffuse alveolar haemorrhage secondary to a perinuclear ANCA-associated vasculitis. To our ...
Humoral immune response of SARS-CoV-2-infected patients with cancer: influencin...
Esperança Martins, Miguel; Gonçalves, Lisa; Soares De Pinho, Inês; Gomes, Andreia; Montesinos Serrano, Marta; Blankenhaus, BirteBackground: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients with cancer show worse outcomes compared with patients without cancer. The humoral immune response (HIR) of patients with cancer against SARS-CoV-2 is not well characterized. To better understand it, we conducted a serological study of hospitalized patients with cancer infected with SARS-CoV-2. Materials and methods: This...